Using our neuNanoParticle^® Technology platform, Formatech has developed neuPaclitaxel; a reformulated paclitaxel drug that provides improved safety, tolerability and efficacy versus Taxol^®1 and Abraxane^®2.

Paclitaxel is a commonly prescribed medication for use in the treatment of breast, ovarian, non-small cell lung cancers, and AIDS related Kaposi's sarcoma. Paclitaxel is a hydrophobic compound that is difficult to formulate as an injectable product. Marketed products require the use of undesirable excipients (i.e. cremophor or human serum albumin) to render the compound suitable for injection. These reagents, while approved for use in humans, expose patients to additional risk (hypersensitivity reactions and exposure to blood borne pathogens, respectively).

After applying our neuNanoParticle Technology methods, neuPaclitaxel provides the following benefits:

• Absence of excipient based undesirable side effects such as hypersensitivity, nephrotoxicity, and neurotoxicity
• The formulation does not contain any solvents or surfactants that are known to trigger adverse reactions, therefore pre-medication with corticosteroids will not be required
• The use of human serum derived proteins is not required, eliminating the patient's potential for exposure to blood borne pathogens (HIV, Hepatitis, etc.)
• The formulation can be lyophilized, improving product shelf-life
• Shorter infusion rates reduce the amount of time required for outpatient treatments

neuPaclitaxel pre-clinical data.

¹Taxol is a registered trademark of Bristol-Myers Squibb.
²Abraxane is a registered trademark of Abraxis Bioscience.

 

neuDocetaxel Program

---

neuPaclitaxel Data

---

neuPropofol Program